€1.823 billion revenue (FY 2018) (approximately 234.0 billion yen)

92.3% of revenue from prescription ophthalmic pharmaceuticals (FY2018)

Overseas sales accounts for 31.4% of corporate revenue (FY 2018)

Over 4,070+ employees globally (as of end of March 2019)

Products supplied in over 60 countries 

Dedicated facilities for ongoing research and development: Nara Research and Development Centre (Japan), Evry (France), Tampere (Finland), Emeryville (US)

Three manufacturing sites: Noto and Shiga (Japan), Suzhou (China)